-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $5

Benzinga·04/02/2026 10:37:53
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price target from $6 to $5.